FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors


Treating diabetes with dipeptidyl peptidase-iv inhibitors

Merck Sharp & Dohme Corp.

Treating diabetes with dipeptidyl peptidase-iv inhibitors

Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15Mono- and di-peg il-10 production; and uses
22015001159001/08/15Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52015017553406/25/15 new patent  Alpha-7 nicotinic acetylcholine receptor modulators and uses therof-i
62015017557506/25/15 new patent  Imidazolyl analogs as syk inhibitors
72015017560906/25/15 new patent  Treating diabetes with dipeptidyl peptidase-iv inhibitors
82015016648606/18/15Substituted diazine and triazine spleen tyrosine kinease (syk) inhibitors
92015016649006/18/15Mineralocorticoid receptor antagonists
102015016652006/18/15Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
112015015893506/11/15Protective vaccine based on staphylococcus aureus sa2493 protein
122015015099006/04/15Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
132015015212706/04/15Permeable glycosidase inhibitors and uses thereof
142015014733705/28/15Crystalline anti-human il-23 antibodies
152015014824605/28/15Surface anchored light chain bait antibody display system
162015014832705/28/15Substituted pyridine spleen tyrosine kinase (syk) inhibitors
172015013998605/21/15Ilt3 binding molecules and uses therefor
182015014142805/21/15Trka kinase inhibitors, compositions and methods thereof
192015014144405/21/15N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
202015012644305/07/15Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
212015012649305/07/15Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease
222015011939404/30/15Insulin-like growth factor-1 receptor inhibitors
232015011186604/23/15Cyclic amine substituted heterocyclic cetp inhibitors
242015011187704/23/15Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
252015011191404/23/15Spirolactam cgrp receptor antagonists
262015010445304/16/15Fdf03 antibodies and uses thereof
272015010446504/16/15Il-19 as a biomarker of tslp treatment
282015010531704/16/15Glucose-responsive insulin conjugates
292015010535404/16/15Heterocyclic aspartyl protease inhibitors
302015009989104/09/15Novel crystalline forms of a dipeptidyl peptidase-iv inhibitors
312015009971504/09/15Formulations of acadesine
322015009971904/09/15Cathepsin cysteine protease inhibitors
332015009972904/09/15Inhibitors of the renal outer medullary potassium channel
342015009977104/09/15Pyridine cgrp receptor antagonists
352015009339804/02/15Methods and compositions for treating or preventing cancer
362015008390603/26/15Biomarkers for monitoring intervention therapies for diabetes
372015008764103/26/15Heterocyclic cgrp receptor antagonists
382015008783203/26/15Process for making beta 3 agonists and intermediates
392015007899603/19/15Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
402015007903103/19/15Use of pegylated il-10 to treat cancer
412015008059803/19/15Asymmetric synthesis for preparing fluoroleucine alkyl esters
422015006419203/05/15Mammalian cell surface antigens; related reagents
432015005619102/26/15Igf1 biomarker for igf1r inhibitor therapy
442015005122702/19/15Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
452015005124802/19/15Imidazolyl methyl piperidine t-type calcium channel antagonists
462015004425002/12/15Vaccines against clostridium difficile comprising recombinant toxins
472015004534602/12/15Selective glycosidase inhibitors and uses thereof
482015004557502/12/15Process for preparing fluoroleucine alkyl esters
492015003849002/05/15Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
502015003849802/05/15Thrombin inhibitors
512015003850202/05/15Isoxazolopyridine orexin receptor antagonists
522015003870702/05/15Process for making cgrp receptor antagonists
532015003171301/29/15Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
542015003171601/29/15Piperidinone carboxamide azaindane cgrp receptor antagonists
552015003189101/29/15Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
562015002080601/22/15Dry powder inhaler for delivering multipe agglomerate formulations
572015002395201/22/15Anti-addl monoclonal antibody and uses thereof
582015002407101/22/15Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
592015002504601/22/15Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists
602015001768601/15/15Methods for reducing mannosyltransferase activity in lower eukaryotes
612015001839901/15/15Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
622015001056401/08/15Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
632015000460801/01/15Monocyte-derived nucleic acids and related compositions and methods
642015000533001/01/15Piperidinone carboxamide azaindane cgrp receptor antagonists
652014037726012/25/14Protective vaccine based on staphylococcus aureus sa2074 protein
662014037849312/25/14Fused bicyclic oxazolidinone cetp inhibitor
672014037002512/18/14Uses of mammalian cytokines and agonists; related reagents
682014037113812/18/14Inhibitors of hepatitis c virus replication
692014034997211/27/14Substituted pyrimidines
702014034884111/27/14Anti-gitr antibodies
712014034999811/27/14Pyrrolopyrimidines as janus kinase inhiitors
722014035000211/27/14Imidazopyridin-2-one derivatives
732014034307111/20/14Compositions and methods for treating cancer
742014033619611/13/14Phosphoric acid salts of sitagliptin
752014032927611/06/14Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
762014032351910/30/14Heterocyclic compounds as b-raf inhibitors for treatment of cancer
772014029620210/02/14Substituted piperidinyl compounds useful as gpr119 agonists
782014029622110/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
792014029622210/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
802014027501709/18/14Cgrp receptor antagonists
812014025681809/11/14Nano-suspension process
822014024428908/28/14Cold storage system for storing pharmaceutical product containers
832014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
842014023430108/21/14Modulation of pilr to treat immune disorders
852014023553708/21/14N-glycosylated insulin analogues
862014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
872014022722308/14/14Pegylated interleukin-10
882014022725008/14/14Stable formulations of antibodies to tslp
892014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
902014022729208/14/14Anti-mcam antibodies and associated methods of use
912014022002708/07/141d05 pcsk9 antagonists
922014022138308/07/14Cetp inhibitors
932014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
942014020656307/24/14Biomarkers for psoriasis
952014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
962014020664107/24/14Remedy
972014020666507/24/14Selective glycosidase inhibitors and uses thereof
982014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
992014020671507/24/14Preparation and use of compounds as protease inhibitors
1002014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1012014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
1022014017015406/19/14Engineered anti-il-23r antibodies
1032014017065806/19/14Mammalian cytokines; related reagents
1042014017143706/19/14Oxazole derivatives useful as inhibitors of faah
1052014017145606/19/14Fused tricyclic compounds as mtor inhibitors
1062014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
1072014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
1082014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
1092014014744205/29/14Use of il-23 antagonists for treatment of infection
1102014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
1112014014095405/22/14Methods of modulating cytokine activity; related reagents
1122014014101205/22/14Engineered anti-tslp antibody
1132014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
1142014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
1152014014211505/22/14Inhibitors of the renal outer medullary potassium channel
1162014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
1172014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
1182014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
1192014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
1202014011291904/24/14Interleukin-10 antibodies
1212014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1222014010588704/17/14Methods for modulating il-33 activity
1232014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
1242014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
1252014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
1262014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
1272014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
1282014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
1292014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
1302014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1312014004574602/13/14Antidiabetic tricyclic compounds
1322014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
1332014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
1342014003762702/06/14Modulation of pilr receptors to treat microbial infections
1352014003894202/06/14Rorgammat inhibitors
1362014003897002/06/14Bridged and fused antidiabetic compounds
1372014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
1382014003076001/30/14Pavec
1392014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
1402014003134901/30/14Inhibitors of the renal outer medullary potassium channel
1412014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1422014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1432013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
1442013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
1452013032323912/05/13Modulation of pilr receptors to treat sepsis
1462013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
1472013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
1482013032448312/05/13Mammalian cell surface antigens; related reagents
1492013032461012/05/13Cathepsin cysteine protease inhibitors
1502013032472812/05/13Process for the preparation of an orexin receptor antagonist
1512013031635411/28/13Mammalian cytokine; related reagents
1522013029627811/07/13Diazeniumdiolate derivatives
1532013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
1542013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
1552013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
1562013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1572013025167709/26/13Genetic markers associated with interferon-alpha response
1582013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
1592013023751809/12/13Novel compounds that are erk inhibitors
1602013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
1612013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1622013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1632013021657508/22/13Recombinant subunit dengue virus vaccine
1642013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1652013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1662013021776608/22/13Formulations for cathepsin k inhibitors
1672013020306008/08/13Mammalian genes; related reagents
1682013018927807/25/13Antagonists of pcsk9
1692013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1702013015672906/20/13Mammalian receptor proteins; related reagents and methods
1712013015677106/20/13Fdf03 antibodies and uses thereof
1722013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1732013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1742013013104105/23/13Spirocyclic compounds
1752013013104205/23/13Spiroxazolidinone compounds
1762013012200905/16/13Engineered anti-il-23p19 antibodies
1772013012320005/16/13Mammalian cell surface antigens; related reagents
1782013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1792013011522305/09/13Antagonists of pcsk9
1802013011623105/09/13Tyrosine kinase inhibitors
1812013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1822013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1832013007139003/21/13Method for preparing antibodies having improved properties
1842013006481703/14/13Engineered anti-il-23r antibodies
1852013005985003/07/13Aza-indole derivatives useful as modulators of faah
1862013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1872013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1882013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1892013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1902013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1912013003531202/07/13Cathepsin cysteine protease inhibiors
1922013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1932013001804801/17/13Oxazole derivatives useful as modulators of faah
1942013001252601/10/13Oxazole derivatives useful as modulators of faah
1952013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1962013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1972012032967912/27/12Eukaryotic cell display systems
1982012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1992012031620012/13/12Pyridone derivatives
2002012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
2012012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
2022012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
2032012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
2042012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
2052012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2062012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
2072012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
2082012019690108/02/12Tertiary amide orexin receptor antagonists
2092012019070107/26/12Renin inhibitors
2102012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
2112012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
2122012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2132012016415806/28/12Anti-addl monoclonal antibody and use thereof
2142012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
2152012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
2162012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
2172012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
2182012014275206/07/12Hiv protease inhibitors
2192012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
2202012012162405/17/12Hepatitis c virus ns3 protease inhibitors
2212012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
2222012012150805/17/12Radiolabeled cgrp antagonists
2232012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
2242012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
2252012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
2262012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
2272012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
2282012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
2292012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
2302012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
2312012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2322012008348304/05/12Inhibitors of hepatitis c virus replication
2332012008267904/05/12Antagonists of pcsk9
2342012008268004/05/12Antagonists of pcsk9
2352012007679903/29/12Antagonists of pcsk9
2362012007796403/29/12Antagonists of pcsk9
2372012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
2382012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
2392012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
2402012003521402/09/12Renin inhibitors
2412012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
2422012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
2432012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
2442012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
2452012002107401/26/12P2x3, receptor antagonists for treatment of pain
2462012002194801/26/12Surface display of whole antibodies in eukaryotes
2472012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
2482012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
2492012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE